Monitoring the Decrease of Circulating Malignant T Cells in Cutaneous T-Cell Lymphoma During Photopheresis and Interferon Therapy

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

“…Malignant T cells have a T CM phenotype in L-CTCL and a T EM phenotype in MF Clonal malignant T cells can be identified in some CTCL patients by staining with commercially available antibodies to T cell receptor (TCR) Vb subfamilies. By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and the skin of L-CTCL patients coexpressed L-selectin and CCR7, a phenotype characteristic of T CM (6) (Fig.…”

“…By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and skin of L-CTCL patients co-expressed L-selectin and CCR7, a phenotype characteristic of T CM (6)(Fig.…”

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

“…Malignant T cells have a T CM phenotype in L-CTCL and a T EM phenotype in MF Clonal malignant T cells can be identified in some CTCL patients by staining with commercially available antibodies to T cell receptor (TCR) Vb subfamilies. By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and the skin of L-CTCL patients coexpressed L-selectin and CCR7, a phenotype characteristic of T CM (6) (Fig.…”

“…By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and skin of L-CTCL patients co-expressed L-selectin and CCR7, a phenotype characteristic of T CM (6)(Fig.…”

Evolution of Clinical and Molecular Responses to Bexarotene Treatment in Cutaneous T-Cell Lymphoma

“…Our study demonstrates no direct activity on T-cell clones. It has been suggested that the presence or absence of T-cell clone in blood during the course of treatment may be a useful tool to predict response to bexarotene therapy [15]. Our study is the first of its kind concerning the evolution of the T-cell clone both in skin and blood during bexarotene therapy.…”

Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction

“…Consistent with other studies, in patients where a TCR-Vβ clone is detectable, it may be useful to continue to monitor tumor burden by TCR-Vβ expression. 20,24,25 …”

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

“…Malignant T cells have a T CM phenotype in L-CTCL and a T EM phenotype in MF Clonal malignant T cells can be identified in some CTCL patients by staining with commercially available antibodies to T cell receptor (TCR) Vb subfamilies. By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and the skin of L-CTCL patients coexpressed L-selectin and CCR7, a phenotype characteristic of T CM (6) (Fig.…”

“…By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and skin of L-CTCL patients co-expressed L-selectin and CCR7, a phenotype characteristic of T CM (6)(Fig.…”

Evolution of Clinical and Molecular Responses to Bexarotene Treatment in Cutaneous T-Cell Lymphoma

“…Our study demonstrates no direct activity on T-cell clones. It has been suggested that the presence or absence of T-cell clone in blood during the course of treatment may be a useful tool to predict response to bexarotene therapy [15]. Our study is the first of its kind concerning the evolution of the T-cell clone both in skin and blood during bexarotene therapy.…”

Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction

“…Consistent with other studies, in patients where a TCR-Vβ clone is detectable, it may be useful to continue to monitor tumor burden by TCR-Vβ expression. 20,24,25 …”

Skin Effector Memory T Cells Do Not Recirculate and Provide Immune Protection in Alemtuzumab-Treated CTCL Patients

“…Malignant T cells have a T CM phenotype in L-CTCL and a T EM phenotype in MF Clonal malignant T cells can be identified in some CTCL patients by staining with commercially available antibodies to T cell receptor (TCR) Vb subfamilies. By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and the skin of L-CTCL patients coexpressed L-selectin and CCR7, a phenotype characteristic of T CM (6) (Fig.…”

“…By identifying the malignant T cell clone, researchers can assess disease burden and monitor for recurrence (7). As reported previously, clonal malignant T cells from both the blood and skin of L-CTCL patients co-expressed L-selectin and CCR7, a phenotype characteristic of T CM (6)(Fig.…”

Evolution of Clinical and Molecular Responses to Bexarotene Treatment in Cutaneous T-Cell Lymphoma

“…Our study demonstrates no direct activity on T-cell clones. It has been suggested that the presence or absence of T-cell clone in blood during the course of treatment may be a useful tool to predict response to bexarotene therapy [15]. Our study is the first of its kind concerning the evolution of the T-cell clone both in skin and blood during bexarotene therapy.…”

Cutaneous T-cell lymphoma (CTCL): Current practices in blood assessment and the utility of T-cell receptor (TCR)-Vβ chain restriction

“…Consistent with other studies, in patients where a TCR-Vβ clone is detectable, it may be useful to continue to monitor tumor burden by TCR-Vβ expression. 20,24,25 …”